Navigation Links
Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data

any future results, performance or achievements expressed or implied by such forward-looking statements. Statements of "belief" with respect to reformulation, the undertaking of an additional clinical trial for CRD5 as well as CRD5's efficacy in raising HDL levels, are based primarily upon results derived to date from the Company's pre-clinical research and development and its results from completed Phase I and Phase I/II clinical trials. While the Company believes that it has reasonable scientific basis upon which to make such statements, it is not possible to predict whether a new therapeutic agent will be prove to be safe and/or effective in humans. The Company cannot guarantee that it actually will achieve the plans, intentions or expectations. and undue reliance should not be placed on those forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's periodic regulatory filings, which can be found in the SEDAR database at www.sedar.com.

For further information: Investor Relations Joanna Longo The Equicom Group Inc. (416) 815-0700 ext. 233 jlongo@equicomgroup.com

Media Relations Linda Forrest inmedia Public Relations (613) 234-7227 ext. 234 lforrest@inmedia.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Further Analysis CRD5 Phase Clinical Trial Data
(Date:1/6/2009)...E, Md., Jan. 6 Sequella... focused on diseases of epidemic potential, announ...the treatment of tuberculosis (TB), was the first ...inical program contract to Dynport Vaccine Company...arded by the National Institute of Allergy and Inf...
(Date:1/5/2009)...ESDA, Md., Jan. 5 Microm...ompany developing novel, proprietary,antibodies f...mmune diseases,provides an outlook on key events...t intends to provide an update on its research and..., -- April 12 to 16, 2009: Update on several ...
(Date:12/27/2008)...D,S, Bermuda, Dec. 23 Wa...today that one of its subsidiaries and Mayne Pharm...of Hospira, Inc., have filed lawsuits against each..., Mylan Pharmaceuticals Inc. ("Mylan") and Impax L... for the District of New Jersey for infringement o...
(Date:12/17/2008)...est, Most Complex of Its Kind; 80 Percent of Traum..., Dec. 17 A multi-disciplinary tea...ntly performed the first near-total face transpla...procedure performed within the past two weeks, sur...o suffered severe facial trauma -- essentially rep...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Six Positive Predictions for 2008 from SuperLife World Service 8518 1Six Positive Predictions for 2008 from SuperLife World Service 8518 2ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 1ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 2China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 1China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 2AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 1AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 2
...ce suggests that if you,could choose your parents,...ase. Researchers from the long-standing,Framingham...t,Lung, and Blood Institute (NHLBI) of the Nation...parents live longer were more,likely to avoid deve...other risk factors for cardiovascular disease in m...
...3, 2007 -,Cytos Biotechnology AG (SWX:CYTN) report...ith CYT003-QbG10, an immunotherapeutic,product can... study,included 40 patients suffering from mild to...lergy (hay fever). The trial,investigated in a dou...oratory efficacy of two different formulations of ...
Other Medicine Technology:Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 2Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
(Date:1/8/2009)...e introduces Senator Daschle at his confirmation h...n Services , , , WASHINGTON, Jan. 8 /PRNewswi...ounding board member Senator Tom Daschle, nominee ...ary, was introduced by fellow BPC founder and frie...day. The hearing was convened by the Senate Health...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)...lowered bad cholesterol more effectively than Zoco...-- After nearly a year of review, U.S. health offi...ued use of the controversial cholesterol-lowering ...ration said there was no significant difference in...Vytorin and patients taking the drug Zocor. , B...
(Date:1/8/2009)... local dance students will dance to raise money fo...IS, Jan. 8 , , , WHO: ...show off their talent in the 3rd annual Dance, ...ance Arts Centre. The, event will..., Participants raise money throu...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Dance With Courage to Benefit Camp Courage 2
...a steroid nasal spray to quash allergy symptoms ma...s say that when used on an "as-needed'', rather th...se) relieves// allergy symptoms such as runny nose...vely than the antihistamine loratadine (Claritin)....
...on of intravenous magnesium sulfate to standard em...amide, appears to reduce rather than enhance the e...olleagues from the Albert Einstein College of Medi...vidence that magnesium may be helpful in the treat...
...who smoke during pregnancy are more likely to bear...higher risk than others because of genetic suscept...determine the causes of low birth weight, though t...mmending at this point that women be screened for ...
... of Swiss researchers found that butterbur extract...fects. Mr John de Carpentier said,presumably it co... would not work - and therefore it is possible tha...ons. It was used in treating hayfever The researc...
Other Medicine News:
Aluminum Stylette 16 with Adjustable Stop.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Aluminum Stylette 16.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Medicine Products: